ChemLifeIntel/Companies/Insilico Medicine

Insilico Medicine

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 3 of 3 briefs on Insilico Medicine

MARKET INTELLIGENCE·CDMO Deal

Insilico Medicine's $2.5 Billion Bora Pharmaceuticals Deal Signals Escalating AI Impact on CDMO Market

Insilico Medicine, a generative AI specialist, has partnered with CDMO Bora Pharmaceuticals in a collaboration potentially valued at $2.5 billion in milestones. This deal underscores the escalating integration of AI in drug discovery and development, signaling significant shifts for procurement, supply chain, and regulatory functions. For CDMOs, securing such high-value, AI-driven partnerships is critical for future growth and market relevance.

90-Day Activity

Insilico Medicine

RARobert Ashworth· Principal Intelligence Analyst

13d ago CDMO Deal

MARKET INTELLIGENCE·CDMO Deal

Insilico Medicine and Takeda Forge $600M AI Drug Discovery Alliance, Signaling Shift in Pharma R&D

Insilico Medicine and Takeda have formed a strategic collaboration, valued at up to $600 million plus royalties, to accelerate AI-driven drug discovery across Takeda’s therapeutic areas. Insilico will leverage its Pharma.AI platform for candidate identification, while Takeda assumes clinical development, manufacturing, and commercialization rights. This deal underscores the growing reliance on AI to de-risk and expedite pharmaceutical pipelines, impacting future procurement and supply chain strategies for novel therapeutics.

90-Day Activity

Insilico Medicine

RARobert Ashworth· Principal Intelligence Analyst

26d ago CDMO Deal

MARKET INTELLIGENCE·CDMO Deal

Insilico Medicine and SK Biopharmaceuticals Forge $2.5B AI-Driven CNS Drug Discovery Alliance

Insilico Medicine and SK Biopharmaceuticals have initiated a drug discovery collaboration valued up to $2.5 billion for neuroimmune disorders. This alliance leverages Insilico's Pharma.AI platform for preclinical development, with SK Biopharmaceuticals leading late-stage development and commercialization. This signals a critical shift towards AI-accelerated R&D in CNS, impacting future procurement and supply chain strategies for novel therapies.

90-Day Activity

Insilico Medicine

RARobert Ashworth· Principal Intelligence Analyst

2026-06-22▲ Trending signal